Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Atea Pharmaceuticals (AVIR)
NASDAQ:AVIR
RESEARCH TOOLSreports
Holding AVIR?
Track your performance easily
Earnings Data
Report Date
Mar 04, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.29Last Year’s EPS
-$0.47Same Quarter Last Year
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 07, 2024
|% Change Since: -7.27%
|Next Earnings Date:Mar 04, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook for Atea Pharmaceuticals, with a strong financial position and promising progress in their HCV program. However, the challenges with the SUNRISE-3 trial and patient adherence issues present areas of concern.Company Guidance
During Atea Pharmaceuticals' Q3 2024 earnings call, the company provided several key metrics and guidance for its ongoing and future programs. They reported $492.8 million in cash, cash equivalents, and marketable securities as of September 30, ensuring financial runway into 2027. Atea is focused on its global HCV program, with Phase II top-line results expected in early December and a Phase III initiation planned for early next year. The company aims to address the unmet needs of HCV patients, with approximately 100,000 new chronic cases annually in the U.S. The Phase III program will involve over 100 sites across the U.S., and the company remains confident in its regulatory strategy, anticipating an end-of-Phase II meeting with the FDA early next year.Strong Financial Position
Atea Pharmaceuticals has $492.8 million in cash, cash equivalents, and marketable securities as of September 30, 2024, providing a financial runway well into 2027.
Progress in HCV Program
The global HCV program remains on track, with Phase II study results expected in early December and preparation for Phase III trials underway.
Phase II HCV Study Success
The Phase II HCV trial showed a 97% SVR12 rate in a leading cohort of 60 patients with a short 8-week treatment duration, indicating a strong potential for efficacy in future studies.
Market Opportunity for HCV
The U.S. HCV market remains large, with net sales of approximately $1.5 billion, and a growing demand due to a consistent influx of new chronic cases annually.
---
AVIR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
AVIR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $3.44 | $3.50 | +1.74% |
| Aug 07, 2024 | $3.27 | $3.50 | +7.03% |
| May 14, 2024 | $3.96 | $3.71 | -6.31% |
| Feb 28, 2024 | $4.37 | $4.31 | -1.37% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Atea Pharmaceuticals (AVIR) report earnings?
Atea Pharmaceuticals (AVIR) is schdueled to report earning on Mar 04, 2025, TBA Not Confirmed.
What is Atea Pharmaceuticals (AVIR) earnings time?
Atea Pharmaceuticals (AVIR) earnings time is at Mar 04, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AVIR EPS forecast?
AVIR EPS forecast for the fiscal quarter 2024 (Q4) is -$0.29.
---